It is now important for the European Medicines Agency to recognize and integrate into its regulatory processes these new methods of in silico simulation and prediction.
With the help of in silico models we can integrate the right patients in clinical trials and reduce the size of these trials.
Anything that will contribute upstream to better mechanistic knowledge and to improved selection of responder patients will be welcome. I think that there is a whole avenue opening up for in silico modeling in oncology today.
In silico is truly a new method of medical research investigation. Digital technology is used to be able to reduce as much as possible the experiments to be performed: animal testing and of course trials in patients.
Boissel JP, Auffray C, Denis Noble, Hood L, Boissel FH | CPT Pharmacometrics Syst. Pharmacol 2015; 4, e26